Hematologic Response to Amifostine
| . | No. Evaluable . | No. of Responders . | Net Change . |
|---|---|---|---|
| ANC ≥50% increase | 18 | 14 (78%) | [426-11,348/μL] |
| Pretreatment ANC <1,000/μL | 12 | 9 (75%) | |
| Pretreatment ANC >1,000/μL | 6 | 5 | |
| Platelets ≥50% increase* | 14 | 6 (43%) | [16-110,000/μL] |
| Pretreatment <50,000/μL* | 8 | 2 | |
| Pretreatment >50,000/μL | 6 | 4 | |
| Reticulocytes ≥50% increase | 16 | 8 (50%) | [1.3-4.1] |
| RBC transfusions ≥50% reduction | 15 | 5 (33%) |
| . | No. Evaluable . | No. of Responders . | Net Change . |
|---|---|---|---|
| ANC ≥50% increase | 18 | 14 (78%) | [426-11,348/μL] |
| Pretreatment ANC <1,000/μL | 12 | 9 (75%) | |
| Pretreatment ANC >1,000/μL | 6 | 5 | |
| Platelets ≥50% increase* | 14 | 6 (43%) | [16-110,000/μL] |
| Pretreatment <50,000/μL* | 8 | 2 | |
| Pretreatment >50,000/μL | 6 | 4 | |
| Reticulocytes ≥50% increase | 16 | 8 (50%) | [1.3-4.1] |
| RBC transfusions ≥50% reduction | 15 | 5 (33%) |
Exceeding a 15,000/μL platelet increment and ≥50% of baseline.